BioSpace News Archive

Albany NY, United States: A newly compiled business intelligence study at the headquarters of Transparency Market Research has detected stiff competition in the global pulmonary drug delivery systems market.

Curium announced that it will be increasing production capacity of Detectnet to accommodate the significant demand in the market.

Daiichi Sankyo and AstraZeneca have received notification of acceptance of the supplemental Biologics License Application of ENHERTU® for the treatment of adult patients in the U.S. with unresectable or metastatic non-small cell lung cancer whose tumors have a HER2 mutation and who have received a prior systemic therapy.

Ascletis Pharma Inc. announces that its oral small molecule drug candidate ASC11, a 3-chymotrypsin like protease inhibitor, demonstrated potential to be effective treatment for COVID-19.

BioAge Labs, Inc. announced that the first cohort has been dosed in a Phase 1b trial of BGE-105, a highly selective and potent small-molecule agonist of the apelin receptor APJ.

BeiGene announced the presentation of updated data analyses from the Phase 3 RATIONALE-309 trial of tislelizumab, a humanized anti-PD-1 monoclonal antibody, in combination with chemotherapy versus chemotherapy plus placebo as a first-line treatment for patients with recurrent or metastatic nasopharyngeal cancer, at the virtual American Society of Clinical Oncology Plenary Series on April 19, 2022.

Turnstone Biologics Corp. announced the appointments of Venkat Ramanan, Ph.D., as Chief Financial Officer, and P. Joseph Campisi Jr., J.D., M.B.A., as General Counsel.

Johnson & Johnson announced that its Board of Directors has declared a 6.6% increase in the quarterly dividend, from $1.06 per share to $1.13 per share.

Company management presented 2 Phase IIb clinical trial posters at the American Association for Cancer Research (AACR) Annual Meeting 2022, which was held from April 8-13, 2022 in New Orleans, Louisiana.

Genmab A/S announced that worldwide net trade sales of DARZALEX®,including sales of the subcutaneous formulation,as reported by Johnson & Johnson were USD1,856million in the first quarter of 2022.